Aussie IPO for breast cancer imaging player Volpara raises almost $8M

Volpara Health Technologies ($VHT) has raised A$10 million ($7.6 million) in an IPO that values it at about $61 million. The company markets a suite of breast imaging tools for personalized breast cancer screening based on objective measurements of volumetric breast density, compression and radiation dose. More than 9 million women in over 30 countries have been examined with its technology. Volpara will use the IPO funds to expand its sales team, increase marketing in the U.S. and Europe, launch new products and incorporate predictive analytics. "To list on the ASX is a significant milestone which enables Volpara to accelerate its growth globally, as well as expand its ability to apply industry-leading digital health solutions to support the paradigm shift to personalized breast cancer screening that is being driven by women demanding better information, better screening systems, better healthcare and better results," said Volpara CEO Ralph Highnam in a statement. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.